0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      24-Hour Rhythm of Hypothalamic Melatonin Immunofluorescence Correlates with Serum and Retinal Melatonin Rhythms

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The 24-hour rhythm of retinal and hypothalamic melatonin immunofluorescence was determined in male albino rats and compared to the 24-hour rhythm of serum melatonin determined by radioimmunoassay. Under a 12-hour (0:00–12:00):12-hour dark cycle, the 24-hour rhythm of melatonin immunocytochemical fluorescence in the retina was bio-modal (crests at 1:00 and 10:00–13:00). In serum, melatonin has a single crest late in the dark period (18:00). In the hypothalamus melatonin immunofluorescence showed increments corresponding to the crests in retina (13:00) and serum (18:00). In a 2-hour light: 22-hour dark cycle, the retinal rhythm was suppressed, the serum rhythm unchanged, and the hypothalamic rhythm had a single crest corresponding to the crest of the serum melatonin rhythm. These data indicate that the 24-hour hypothalamic rhythm of melatonin immunofluorescence may be secondary to the serum and retinal 24-hour rhythms of melatonin.

          Related collections

          Author and article information

          Journal
          NEN
          Neuroendocrinology
          10.1159/issn.0028-3835
          Neuroendocrinology
          S. Karger AG
          0028-3835
          1423-0194
          1982
          1982
          26 March 2008
          : 34
          : 5
          : 363-368
          Affiliations
          aDepartment of Psychiatry, University of Rochester, N.Y., USA; bDepartment of Neurosciences, McMaster University, Hamilton, Ont., Canada
          Article
          123329 Neuroendocrinology 1982;34:363–368
          10.1159/000123329
          7043301
          © 1982 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Categories
          Original Paper

          Comments

          Comment on this article